Trying to be objective, acknowledging adverse poss
Post# of 72440
(Total Views: 411)
Posted On: 06/28/2017 8:31:25 PM
Trying to be objective, acknowledging adverse possibilities for a speculative investment (btw, I am HEAVILY long).
IPIX will need the right partnership or the entire pipeline stalls at mid-stage. The B-UP is a proof of concept with no placebo arm. That's a great financial approach, but a wider p2 will likely be required at the maximum dose (likely with a foam formulation). After completing a Kevetrin p2 and the current trials, will they have the ~$30M for a phase 3? No.
So again, call it what you will, if not life support - call it a deepening financial hole. Appropriately Leo et. al. have indeed emphasized that a partnership is a top priority NOW. And a big pharma suitor will play to that if they are the only player.
Several recent pharma deals have been shown to be less fruitful than advertised if not complete busts. For some it has been a sobering 2 months after cash flowed in recent years to supplant shrinking in-house R&D funding.
So again at what cost this summer for B-UP, B-OM or Purisol? Or a deal for all for the pipeline, labware and talented employees in Beverly (perhaps Leo et. al. stay on with the pharma subsidiary and nice onboard packages?
I may be way off, but if I am I'll make out even better, as will most of you. But be not surprised if that big payoff is less than most of you may think.
IPIX will need the right partnership or the entire pipeline stalls at mid-stage. The B-UP is a proof of concept with no placebo arm. That's a great financial approach, but a wider p2 will likely be required at the maximum dose (likely with a foam formulation). After completing a Kevetrin p2 and the current trials, will they have the ~$30M for a phase 3? No.
So again, call it what you will, if not life support - call it a deepening financial hole. Appropriately Leo et. al. have indeed emphasized that a partnership is a top priority NOW. And a big pharma suitor will play to that if they are the only player.
Several recent pharma deals have been shown to be less fruitful than advertised if not complete busts. For some it has been a sobering 2 months after cash flowed in recent years to supplant shrinking in-house R&D funding.
So again at what cost this summer for B-UP, B-OM or Purisol? Or a deal for all for the pipeline, labware and talented employees in Beverly (perhaps Leo et. al. stay on with the pharma subsidiary and nice onboard packages?
I may be way off, but if I am I'll make out even better, as will most of you. But be not surprised if that big payoff is less than most of you may think.
(0)
(4)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼